Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice

Brain Research

Volumn 1491, Issue , 2013, Pages 236-250

  Li, Li ^a,b   Qiu, Guozhen ^a   Ding, Shengyuan ^a   Zhou, Fu Ming ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

5 HT2A receptor; Basal ganglia; Dopamine; Dyskinesia; l 3, 4 dihydroxyphenylalanine (l dopa); Parkinson's disease; qRT PCR; Striatum

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; DOPAMINE; LEVODOPA; MESSENGER RNA; SEROTONIN; SEROTONIN 2A RECEPTOR; TRANSCRIPTION FACTOR PITX3; VOLINANSERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC INNERVATION; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DOPAMINE DEFICIENT MOUSE; DYSKINESIA; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MOTOR ACTIVITY; MOUSE; NERVE STIMULATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; UPREGULATION;

ANIMALS; BASAL GANGLIA; DOPAMINE; DYSKINESIAS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HOMEODOMAIN PROTEINS; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; MUTATION; NEOSTRIATUM; NERVE NET; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, SEROTONIN, 5-HT2A; RNA; SEROTONIN; SEROTONIN ANTAGONISTS; SUBSTANTIA NIGRA; TRANSCRIPTION FACTORS; UP-REGULATION;

MUS;

EID: 84874018474     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.11.010     Document Type: Article

References (99)

1. R.L. Albin, A.B. Young, and J.B. Penney The functional anatomy of basal ganglia disorders Trends Neurosci. 12 1989 366 375
2. G.J. Basura, and P.D. Walker Serotonin 2A receptor mRNA levels in the neonatal dopamine-depleted rat striatum remain upregulated following suppression of serotonin hyperinnervation Brain Res. Dev. Brain Res. 116 1999 111 117
3. G.J. Basura, and P.D. Walker Stimulated serotonin release from hyperinnervated terminals subsequent to neonatal dopamine depletion regulates striatal tachykinin, but not enkephalin gene expression Brain Res. Mol. Brain Res. 81 2000 80 91
4. H.S. Bateup, E. Santini, W. Shen, S. Birnbaum, E. Valjent, D.J. Surmeier, G. Fisone, E.J. Nestler, and P. Greengard Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors Proc. Natl. Acad. Sci. U. S. A. 107 2010 14845 14850
5. C. Bédard, M.J. Wallman, E. Pourcher, P.V. Gould, A. Parent, and M. Parent Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea Parkinsonism Relat. Disord. 17 2011 593 598
6. J.A. Beeler, Z.F. Cao, M.A. Kheirbek, and X. Zhuang Loss of cocaine locomotor response in Pitx3-deficient mice lacking a nigrostriatal pathway Neuropsychopharmacology 34 2009 1149 1161
7. C. Bishop, and P.D. Walker Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats Neuroscience 121 2003 649 657
8. C. Bishop, J.L. Tessmer, T. Ullrich, K.C. Rice, and P.D. Walker Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism J. Pharmacol. Exp. Ther. 310 2004 687 694
9. P. Bonsi, D. Cuomo, J. Ding, G. Sciamanna, S. Ulrich, A. Tscherter, G. Bernardi, D.J. Surmeier, and A. Pisani Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors Neuropsychopharmacology 32 2007 1840 1854
10. P. Brown, and C.R. Gerfen Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK1/2 map kinase pathway J. Comp. Neurol 498 2006 415 430
11. M.A. Cenci Molecular mechanisms of l-dopa-induced dyskinesia H Steiner, KY Tseng, Handbook of Basal Ganglia Structure and Function 2010 Academic Press San Diego 625 640
12. M.A. Cenci, and C. Konradi Maladaptive striatal plasticity in l-DOPA-induced dyskinesia Prog. Brain Res. 183 2010 209 233
13. 2A receptor in the central nervous system of adult rat J. Comp. Neurol. 409 1999 187 209
14. S. Ding, S.G. Matta, and F.M. Zhou Kv3-like potassium channels are required for sustained high-frequency firing in basal ganglia output neurons J. Neurophysiol. 105 2011 554 570
15. S. Ding, W. Wei, and F.M. Zhou Molecular and functional differences in voltage-activated sodium currents between GABA projection neurons and dopamine neurons in the substantia nigra J. Neurophysiol. 106 2011 3019 3034
16. S. Ding, and F.M. Zhou Profiling voltage-gated potassium channel mRNA expression in nigral neurons using single-cell RT-PCR techniques J. Vis. Exp. 55 2011 e3136
17. Y. Ding, J. Restrepo, L. Won, D.Y. Hwang, K.S. Kim, and U.J. Kang Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease Neurobiol. Dis. 27 2007 11 23
18. Y. Ding, L. Won, J.P. Britt, S.A. Lim, D.S. McGehee, and U.J. Kang Enhanced striatal cholinergic neuronal activity mediates l-DOPA-induced dyskinesia in Parkinsonian mice Proc. Natl. Acad. Sci. U. S. A 108 2011 840 845
19. M. El Atifi-Borel, V. Buggia-Prevot, N. Platet, A.L. Benabid, F. Berger, and V. Sgambato-Faure De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemi-Parkinsonian rat Neurobiol. Disord. 34 2009 340 350
20. S. Fahn Involuntary movements LP. Rowland, In Merritt's Neurology 11th edition 2005 Lippincott Williams & Wilkins Philadelphia 48 52
21. V. Francardo, A. Recchia, N. Popovic, D. Andersson, H. Nissbrandt, and M.A. Cenci Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to l-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease Neurobiol. Disord. 42 2011 327 340
22. P. Gaspar, A. Febvret, and J. Colombo Serotonergic sprouting in primate MTP-induced hemiparkinsonism Exp. Brain Res. 96 1993 100 106
23. C.R. Gerfen, T.M. Engber, L.C. Mahan, Z. Susel, T.N. Chase, F.J. Monsma Jr, and D.R. Sibley D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons Science 250 1990 1429 1432
24. Gerfen, C.R., 2010. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum: aberrant ERK1/2 signaling. In: Steiner, H., Tseng, K.Y. (Eds.), Handbook of Basal Ganglia Structure and Function. Academic Press, San Diego, pp. 491-500.
25. S. Gil, C. Park, J. Lee, and H. Koh The roles of striatal serotonin and l-amino-acid decarboxylase on l-DOPA-induced Dyskinesia in a Hemi-Parkinsonian rat model Cell Mol. Neurobiol. 30 2010 817 825
26. J.G. Greene Current status and future directions of gene expression profiling in Parkinson's disease Neurobiol. Disord. 45 2012 76 82
27. E. Grünblatt, W.J. Schmidt, D.K. Scheller, P. Riederer, and M. Gerlach Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats J. Neural. Transm. 118 2011 1717 1725
28. H. Hall, L. Farde, C. Halldin, C. Lundkvist, and G. Sedvall Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907 Synapse 38 2000 421 431
29. O. Hornykiewicz Chemical neuroanatomy of the basal ganglia - normal and in Parkinson's disease J. Chem. Neuroanat. 22 2001 3 12
30. D. Hoyer, A. Pazos, A. Probst, and J.M. Palacios Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites Brain Res. 376 1986 97 107
31. S.W. Hung, G.M. Adeli, T. Arenovich, S.H. Fox, and A.E. Lang Patient perception of dyskinesia in Parkinson's disease J. Neurol. Neurosurg. Psychiatry 81 2010 1112 1115
32. P. Huot, S.H. Fox, and J.M. Brotchie The serotonergic system in Parkinson's disease Prog. Neurobiol. 95 2011 163 212
33. P. Huot, S.H. Fox, A. Newman-Tancredi, and J.M. Brotchie Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? J. Pharmacol. Exp. Ther. 339 2011 2 8
34. P. Huot, T.H. Johnston, L. Winkelmolen, S.H. Fox, and J.M. Brotchie 5-HT(2A) receptor levels increase in MPTP-lesioned macaques treated chronically with l-DOPA Neurobiol. Aging 33 2012 194.e5 194.e15
35. D.Y. Hwang, P. Ardayfio, U.J. Kang, E.V. Semina, and K.S. Kim Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice Brain Res. Mol. Brain Res. 114 2003 123 131
36. D.Y. Hwang, S.M. Fleming, P. Ardayfio, T. Moran-Gates, H. Kim, F.I. Tarazi, M.F. Chesselet, and K.S. Kim 3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease J. Neurosci. 25 2005 2132 2137
37. R. Katzenschlager, J. Head, A. Schrag, Y. Ben-Shlomo, A. Evans, and A.J. Lees Parkinson's disease research group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD Neurology 71 2008 474 480
38. J.H. Kehne, B.M. Baron, A.A. Carr, S.F. Chaney, J. Elands, D.J. Feldman, R.A. Frank, P.L. van Giersbergen, T.C. McCloskey, M.P. Johnson, D.R. McCarty, M. Poirot, Y. Senyah, B.W. Siegel, and C. Widmaier Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile J. Pharmacol. Exp. Ther. 277 1996 968 981
39. S.J. Kish, J. Tong, O. Hornykiewicz, A. Rajput, L.J. Chang, M. Guttman, and Y. Furukawa Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease Brain 131 2008 120 131
40. A.R. Knight, A. Misra, K. Quirk, K. Benwell, D. Revell, G. Kennett, and M. Bickerdike Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors Naunyn Schmiedeberg's Arch. Pharmacol. 370 2004 114 123
41. C. Konradi, J.E. Westin, M. Carta, M.E. Eaton, K. Kuter, A. Dekundy, M. Lundblad, and M.A. Cenci Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia Neurobiol. Disord. 17 2004 219 236
42. R.M. Kostrzewa, T.A. Reader, and L. Descarries Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain J. Neurochem. 70 1998 889 898
43. A.V. Kravitz, B.S. Freeze, P.R. Parker, K. Kay, M.T. Thwin, K. Deisseroth, and A.C. Kreitzer Regulation of Parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry Nature 466 2010 622 626
44. M. Kuoppamäki, G. Al-Barghouthy, M.J. Jackson, L.A. Smith, N. Quinn, and P. Jenner l-dopadose and the duration and severity of dyskinesia in primed MPTP-treated primates J. Neural Transm. 114 2007 1147 1153
45. Langston, J.W., 1985. MPTP neurotoxicity: an overview and characterization of phases of toxicity. Life Sci. 36, 201-206.
46. N. Laprade, F. Radja, T.A. Reader, and J.J. Soghomonian Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons J. Neurosci. 16 1996 3727 3736
47. Q.H. Li, K. Nakadate, S. Tanaka-Nakadate, D. Nakatsuka, Y. Cui, and Y. Watanabe Unique expression patterns of 5-HT2A and 5-HT2C receptors in the rat brain during postnatal development: Western blot and immunohistochemical analyses J. Comp. Neurol. 469 2004 128 140
48. Y. Li, X.F. Huang, C. Deng, B. Meyer, A. Wu, Y. Yu, W. Ying, G.Y. Yang, M.A. Yenari, and Q. Wang Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats Synapse 64 2010 224 230
49. J.F. López-Giménez, G. Mengod, J.M. Palacios, and M.T. Vilaró Human striosomes are enriched in 5-HT2A receptors: autoradiographical visualization with [3H]MDL100,907, [125I](+/-)DOI and [3H]ketanserin Eur. J. Neurosci. 11 1999 3761 3765
50. M. Lundblad, A. Usiello, M. Carta, K. Håkansson, G. Fisone, and M.A. Cenci Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia Exp. Neurol. 194 2005 66 75
51. V. Luu-The, N. Paquet, E. Calvo, and J. Cumps Improved real-time RT-PCR method for high-throughput measurements using second derivative calculation and double correction Biotechniques 38 2005 287 293
52. T. Maeda, K. Kannari, H. Shen, A. Arai, M. Tomiyama, M. Matsunaga, and T. Suda Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation Neurosci. Lett. 343 2003 17 20
53. G. Mengod, J.M. Palacios, K.H. Wiedrhold, and D. Hoyer 5-hydroxytryptamine receptor histochemistry: comparison of receptor mRNA distribution and radioligand autoradiography in the brain HG Baumgarten, M Gothert, Serotoninergic Neurons and 5-HT Receptors in the CNS 1997 Springer-Verlag Berlin 213 237
54. B.H. Meurers, G. Dziewczapolski, T. Shi, A. Bittner, F. Kamme, and C.W. Shults Dopamine depletion induces distinct compensatory gene expression changes in DARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons J. Neurosci. 29 2009 6828 6839
55. R. Moretti, P. Torre, R.M. Antonello, F. Esposito, and G. Bellini The on-freezing phenomenon: cognitive and behavioral aspects Parkinsons Disord. 2011 2011 746303
56. A. Nadjar, C.R. Gerfen, and E. Bezard Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog. Neurobiol. 87 2009 1 9
57. K. Nielsen, D. Brask, G.M. Knudsen, and S. Aznar Immunodetection of the serotonin transporter protein is a more valid marker for serotonergic fibers than serotonin Synapse 59 2006 270 276
58. R.A. North, and N. Uchimura 5-Hydroxytryptamine acts at 5-HT2 receptors to decrease potassium conductance in rat nucleus accumbens neurones J. Physiol. 417 1989 1 12
59. S. Numan, K.H. Lundgren, D.E. Wright, J.P. Herman, and K.B. Seroogy Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway Brain Res. Mol. Brain Res. 29 1995 391 396
60. I. Nunes, L,T. Tovmasian, R.M. Silva, R.E. Burke, and S.P. Goff Pitx3 is required for development of substantia nigra dopaminergic neurons Proc. Natl. Acad. Sci. U. S. A 100 2003 4245 4250
61. J.G. Nutt, K.A. Chung, and N.H. Holford Dyskinesia and the anti-Parkinsonian response always temporally coincide: a retrospective study Neurology 74 2010 1191 1197
62. C.W. Olanow, M.B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology 72 21 Suppl 4 2009 S1 136
63. A Pazos, R. Cortés, and J.M. Palacios Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors Brain Res. 346 1985 231 249
64. G. Paxinos, and K.B.J. Franklin The Mouse Brain in Stereotaxic Coordinates 2001 Academic Press San Diego, CA
65. D.B. Putterman, A.C. Munhall, L.B. Kozell, J.K. Belknap, and S.W. Johnson Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease J. Pharmacol. Exp. Ther. 323 2007 277 284
66. G. Riahi, M. Morissette, M. Parent, and T. Di Paolo Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias Eur. J. Neurosci. 33 2011 1823 1831
67. R. Raisman, R. Cash, and Y. Agid Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen Neurology 36 1986 556 560
68. M.E. Rice, J.C. Patel, and S.J. Cragg Dopamine release in the basal ganglia Neuroscience 198 2011 112 137
69. J.J. Rodríguez, D.R. Garcia, and V.M. Pickel Subcellular distribution of 5-hydroxytryptamine2A and N-methyl-D-aspartate receptors within single neurons in rat motor and limbic striatum J. Comp. Neurol. 413 1999 219 231
70. G. Rozas, I. Liste, M.J. Guerra, and J.L. Labandeira-Garcia Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice Neurosci. Lett. 245 1998 151 154
71. B. Scholz, M. Svensson, H. Alm, K. Sköld, M. Fälth, K. Kultima, C. Guigoni, E. Doudnikoff, Q. Li, A.R. Crossman, E. Bezard, and P.E. Andrén Striatal proteomic analysis suggests that first l-dopa dose equates to chronic exposure PLoS One 3 2008 e1589
72. R.K. Schwarting, and J.P. Huston The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments Prog. Neurobiol. 50 1996 275 331
73. M.P. Smidt, S.M. Smits, H. Bouwmeester, F.P. Hamers, A.J. van der Linden, A.J. Hellemons, J. Graw, and J.P. Burbach Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3 Development 131 2004 1145 1155
74. S.M. Smits, J.P. Burbach, and M.P. Smidt Developmental origin and fate of mesodiencephalic dopamine neurons Prog. Neurobiol. 78 2006 1 16
75. SM Smits, CW Noorlander, MJ Kas, GM Ramakers, and MP Smidt Alterations in serotonin signalling are involved in the hyperactivity of Pitx3-deficient mice Eur. J. Neurosci 27 2008 388 395
76. J.J. Soghomonian, G. Doucet, and L. Descarries Serotonin innervation in adult rat neostriatum. I. Quantified regional distribution Brain Res. 425 1987 85 100
77. D.G. Standaert, and A.B. Young Treatment of central nervous system degenerative disorders L.L. Brunton, J.S. Lazo, K.L. Parker, Goodman and Gilman's The Pharmacological Basis of Therapeutics 2006 McGraw-Hill New York 527 545
78. D. Stanic, D.I. Finkelstein, D.W. Bourke, J. Drago, and M.K. Horne Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat Eur. J. Neurosci. 18 2003 1175 1188
79. H.W. Steinbusch Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals Neuroscience 6 1981 557 618
80. K.A. Stockwell, D.J. Virley, M. Perren, M.M. Iravani, M.J. Jackson, S. Rose, and P. Jenner Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets Exp. Neurol. 211 2008 172 179
81. J.L. Taylor, C. Bishop., T. Ullrich, K.C. Rice, and P.D. Walker Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat Neuropharmacology 50 2006 761 768
82. T.N. Taylor, J.G. Greene, and G.W. Miller Behavioral phenotyping of mouse models of Parkinson's disease Behav. Brain Res. 211 2010 1 10
83. S.L. Thiele, R. Warre, C.S. Khademullah, N. Fahana, C. Lo, D. Lam, S. Talwar, T.H. Johnston, J.M. Brotchie, and J.E. Nash Generation of a model of l-DOPA-induced dyskinesia in two different mouse strains J. Neurosci. Methods 197 2011 193 208
84. B. Valastro, A. Dekundy, M. Krogh, M. Lundblad, P. James, W. Danysz, G. Quack, and M,A. Cenci Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia J. Neurochem. 102 2007 1395 1409
85. E.J. Van Bockstaele, J. Chan, and V.M. Pickel Pre- and postsynaptic sites for serotonin modulation of GABA-containing neurons in the shell region of the rat nucleus accumbens J. Comp. Neurol. 371 1996 116 128
86. P. van den Munckhof, K.C. Luk, L. Ste-Marie, J. Montgomery, P.J. Blanchet, A.F. Sadikot, and J. Drouin Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons Development 130 2003 2535 2542
87. P. van den Munckhof, F. Gilbert, M. Chamberland, D. Lévesque, and J. Drouin Striatal neuroadaptation and rescue of locomotor deficit by l-dopa in aphakia mice, a model of Parkinson's disease J. Neurochem. 96 2006 160 170
88. C. Verney, C. Lebrand, and P. Gaspar Changing distribution of monoaminergic markers in the developing human cerebral cortex with special emphasis on the serotonin transporter Anat. Rec. 267 2002 87 93
89. Voorn, P., Vanderschuren, L.J., Groenewegen, H.J., Robbins, T.W., Pennartz, C.M., 2004. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci. 27, 468-474.
90. H. Yamada, Y. Aimi, I. Nagatsu, K. Taki, M. Kudo, and R. Arai Immunohistochemical detection of l-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats Neurosci. Res. 59 2007 1 7
91. T.A. Yacoubian, I. Cantuti-Castelvetri, B. Bouzou, G. Asteris, P.J. McLean, B.T. Hyman, and D.G. Standaert Transcriptional dysregulation in a transgenic model of Parkinson disease Neurobiol. Disord. 29 2008 515 528
92. B.Y. Zeng, M.M. Iravani, M.J. Jackson, S. Rose, A. Parent, and P. Jenner Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia Neurobiol Disord. 40 2010 599 607
93. X. Zhang, P.E. Andren, and P. Svenningsson Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model Physiol. Behav. 92 2007 29 33
94. F.C. Zhou, S. Bledsoe, and J. Murphy Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain Brain Res. 556 1991 108 116
95. F.C. Zhou, J.H. Tao-Cheng, L. Segu, T. Patel, and Y. Wang Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence Brain Res. 805 1998 241 254
96. F-M. Zhou, Y. Liang, and J.A. Dani Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum Nat. Neurosci. 4 2001 1224 1229
97. F-M. Zhou, Y. Liang, R. Salas, L. Zhang, M De Biasi, and J.A. Dani Co-release of dopamine and serotonin from striatal dopamine terminals Neuron 46 2005 65 74
98. F.W. Zhou, S.G. Matta, and F.M. Zhou Constitutively active TRPC3 channels regulate basal ganglia output neurons J. Neurosci. 28 2008 473 482
99. F.W. Zhou, Y. Jin, S.G. Matta, M. Xu, and F.M. Zhou An ultra-short dopamine pathway regulates basal ganglia output J. Neurosci. 29 2009 10424 10435